translarna 1000 mg
medison pharma ltd - ataluren - granules for oral suspension - ataluren 1000 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.
translarna 125 mg
medison pharma ltd - ataluren - granules for oral suspension - ataluren 125 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing
translarna 250 mg
medison pharma ltd - ataluren - granules for oral suspension - ataluren 250 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.
translarna 1000 mg
medison pharma ltd - ataluren - granules for oral suspension - ataluren 1000 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.
translarna 125 mg
medison pharma ltd - ataluren - granules for oral suspension - ataluren 125 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing
translarna 250 mg
medison pharma ltd - ataluren - granules for oral suspension - ataluren 250 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.
translarna 125 mg
medison pharma ltd - ataluren - granules for oral suspension - ataluren 125 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testingבקשה לשינוי משטר מינון: 1/12/2020renal impairmentsafety and efficacy of ataluren in patients with renal impairment has not been established. no dosage adjustment is required for patients with mild or moderate renal impairment. treatment of patients with severe renal impairment (egfr <30 ml/min) or end-stage renal disease is not recommended (see sections 4.4 and 5.2).
translarna
ptc therapeutics international limited - ataluren - muscular dystrophy, duchenne - other drugs for disorders of the musculo-skeletal system - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients.the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.
translarna 1000 mg
medison pharma ltd - ataluren - granules for oral suspension - ataluren 1000 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.
translarna 1000 mg
medison pharma ltd - ataluren - granules for oral suspension - ataluren 1000 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.